1st Case To Go To Trial In Neurontin MDL Dropped

Law360, New York (July 30, 2009, 1:28 PM EDT) -- The first individual case to go to trial in the multidistrict litigation over Pfizer Inc.'s alleged campaign to increase profits of Neurontin by encouraging doctors to prescribe the anti-epilepsy drug for off-label uses has been dismissed by the plaintiff's lawyer, according to an attorney for Pfizer.

Mark Lanier of The Lanier Law Firm, who represents the plaintiff, indicated that he wanted to dismiss the case Tuesday in the U.S. District Court for the District of Massachusetts, after opening statements were made and his first witness was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.